


Unlocking Pathology Data to Advance Precision Medicine

Real-Time Access at the Point of Diagnosis



Proscia Aperture™ surfaces patient insights at the moment of diagnosis, enabling biopharma companies to accelerate precision drug development and generate real-world evidence for market access strategies.

Powered by a global network of diagnostic labs reviewing 8M+ cases annually on the Concentriq® enterprise pathology platform, Aperture helps to unlock the pathology data needed to advance novel therapies.

Key Advantages



SPEED

Real-time patient surfacing



SCALE

Diverse, global diagnostic network



DEPTH

Multimodal, AI-enriched data

Delivering Value Across the Precision Medicine Lifecycle




Discovery and Translational

Leverage Proscia's multimodal database to discover novel biomarkers, drug targets, and develop AI-based companion diagnostics.

Clinical Development

Model disease and biomarker prevalence to refine criteria, identify eligible patients at diagnosis, and activate high-performing sites for faster enrollment.




Commercial

Expand access by identifying treatment delays and monitoring real-world effectiveness. Generate evidence for regulatory submissions, CDx development, label expansions, and payer negotiations.


How Aperture Works

Set Eligibility Criteria



Configure complex patient criteria using natural language, with AI process it into structured inputs

Surface Relevant Data with AI



Aperture's AI continuously analyzes real-time daily diagnoses from Proscia's multimodal data lake to identify patients, uncover diagnostic patterns, and generate real-time insights

Monitor Progress and Take Action



Track project and study status via intelligent dashboards and receive notifications in real time as qualified candidates are surfaced


Global Network

Access 8M+ annual cases from a representative and diverse network to accelerate therapy development



Surface Patients at the Point of Diagnosis

Enable the downstream actions below and custom studies tailored to your objectives



Frequently Asked Questions

Can Aperture match patients for rare or biomarker-driven trials?

Yes. Drawing from a global diagnostic network, Aperture provides the scale needed to identify even the smallest, hard-to-find patient populations. The AI interface enables sponsors to define complex inclusion and exclusion criteria through structured queries, delivering precise cohort matching.

How does Aperture integrate with my current Concentriq LS deployment?

Aperture seamlessly integrates with your existing Concentriq LS deployment, creating a unified platform for research and collaboration. The integration enables more robust AI-powered datasets while maintaining your current workflows. Labs retain full control over data sharing and can unlock new revenue streams by connecting their pathology data with pharma partners through the same enterprise platform.

What is the role of AI in powering Aperture?

Aperture leverages AI to rapidly sift through tissue images, biomarkers, molecular results, and clinical records to match patients with the input criteria. AI models on Concentriq also power biomarker detection, image feature extraction, and diagnostic metadata analysis. These results, including quantified tissue morphology, visual phenotypes detection, and feature extraction for trial matching and real-world evidence, are all able to be queried on Concentriq.

Can Aperture support regulatory submissions?

Yes. Aperture's AI-enriched diagnostic data and biomarker monitoring insights can be used to generate regulatory-grade real-world evidence. Sponsors use this data to strengthen FDA and EMA submissions, support label expansions, inform payer negotiations, and accelerate market access for precision therapies. This data is delivered via Concentriq — the same enterprise platform that supports 16 of the top 20 pharmaceutical companies across discovery, development, and commercialization.

"We're not satisfied as scientists, researchers, as clinicians in getting six months longer life average. We want to find cures. There is significant opportunity given where technology is and what it enables us to do by digitizing slides... There's the long-term value of being able to store this data for querying later on. It's beginning to prove that these images, if looked at in the right way, can really help us uncover new answers, new modalities, new opportunities. And be able to drive that earlier, faster, more efficiently."

Ralph Riley

Global Co Diagnostics Market Access Leader
Janssen Global Services

Aperture is now available to select Proscia customers. Contact us to secure your place on the limited early access list today.

Learn more at proscia.com/aperture

| rwd@proscia.com



1700 Market Street, Suite 2450 | Philadelphia, PA 19103
1.215.608.5411 | rwd@proscia.com | proscia.com